{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:24:56Z","timestamp":1771863896491,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although uric acid-lowering agents such as xanthine oxidase inhibitors have potential cardioprotective effects, studies on their use in preventing cardiovascular diseases are lacking. We investigated the genetically proxied effects of reducing uric acid on ischemic cardiovascular diseases in a lipid-level-stratified population. We performed drug-target Mendelian randomization (MR) analyses using UK Biobank data to select genetic instruments within a uric acid-lowering gene, xanthine dehydrogenase (<jats:italic>XDH<\/jats:italic>), and construct genetic scores. For nonlinear MR analyses, individuals were stratified by lipid level. Outcomes included acute myocardial infarction (AMI), ischemic heart disease, cerebral infarction, transient cerebral ischemic attack, overall ischemic disease, and gout. We included 474,983 non-gout individuals with <jats:italic>XDH<\/jats:italic>-associated single-nucleotide polymorphisms. The <jats:italic>XDH<\/jats:italic>-variant-induced uric acid reduction was associated with reduced risk of gout (odds ratio [OR], 0.85; 95% confidence interval [CI], 0.78\u20130.93;<jats:italic> P<\/jats:italic>\u2009&lt;\u20090.001), cerebral infarction (OR, 0.86; 95% CI, 0.75\u20130.98; <jats:italic>P<\/jats:italic>\u2009=\u20090.023), AMI (OR, 0.79; 95% CI, 0.66\u20130.94; <jats:italic>P<\/jats:italic>\u2009=\u20090.010) in individuals with triglycerides\u2009\u2265\u2009188.00\u00a0mg\/dL, and cerebral infarction in individuals with low-density lipoprotein cholesterol (LDL-C)\u2009\u2264\u2009112.30\u00a0mg\/dL (OR, 0.76; 95% CI, 0.61\u20130.96; <jats:italic>P<\/jats:italic>\u2009=\u20090.020) or LDL-C of 136.90\u2013157.40\u00a0mg\/dL (OR, 0.67; 95% CI, 0.49\u20130.92; <jats:italic>P<\/jats:italic>\u2009=\u20090.012). <jats:italic>XDH<\/jats:italic>-variant-induced uric acid reduction lowers the risk of gout, AMI for individuals with high triglycerides, and cerebral infarction except for individuals with high LDL-C, highlighting the potential heterogeneity in the protective effects of xanthine oxidase inhibitors for treating AMI and cerebral infarction depending on the lipid profiles.<\/jats:p>","DOI":"10.1038\/s41598-024-51724-1","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T08:05:18Z","timestamp":1705392318000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of uric acid on ischemic diseases, stratified by lipid levels: a drug-target, nonlinear Mendelian randomization study"],"prefix":"10.1038","volume":"14","author":[{"given":"Jungeun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Yeop","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghyuk","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Gyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunbyeol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho","family":"Gym","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-In","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"51724_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: Update from the GBD 2019 study. J. Am. Coll. Cardiol. 76, 2982\u20133021 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"51724_CR2","unstructured":"World Health Organization. Global Health Estimates 2020: The top 10 causes of death, 2019\u20132020. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death (2020)."},{"key":"51724_CR3","doi-asserted-by":"publisher","first-page":"3A","DOI":"10.1016\/j.amjcard.2009.10.007","volume":"105","author":"B Dahl\u00f6f","year":"2010","unstructured":"Dahl\u00f6f, B. Cardiovascular disease risk factors: Epidemiology and risk assessment. Am. J. Cardiol. 105, 3A-9A (2010).","journal-title":"Am. J. Cardiol."},{"key":"51724_CR4","doi-asserted-by":"publisher","first-page":"19520","DOI":"10.1038\/srep19520","volume":"6","author":"M Li","year":"2016","unstructured":"Li, M. et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci. Rep. 6, 19520 (2016).","journal-title":"Sci. Rep."},{"key":"51724_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","volume":"131","author":"BF Culleton","year":"1999","unstructured":"Culleton, B. F., Larson, M. G., Kannel, W. B. & Levy, D. Serum uric acid and risk for cardiovascular disease and death: The Framingham heart study. Ann. Intern. Med. 131, 7\u201313 (1999).","journal-title":"Ann. Intern. Med."},{"key":"51724_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f4262","volume":"347","author":"TM Palmer","year":"2013","unstructured":"Palmer, T. M. et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. BMJ 347, f4262 (2013).","journal-title":"BMJ"},{"key":"51724_CR7","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1016\/j.bbadis.2018.05.003","volume":"1864","author":"MG Battelli","year":"2018","unstructured":"Battelli, M. G., Bortolotti, M., Polito, L. & Bolognesi, A. The role of xanthine oxidoreductase and uric acid in metabolic syndrome. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 2557\u20132565 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"51724_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13075-016-1111-1","volume":"18","author":"JA Singh","year":"2016","unstructured":"Singh, J. A. & Yu, S. Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: A study of Medicare claims. Arthritis Res. Ther. 18, 209 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"51724_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12883-016-0692-2","volume":"16","author":"JA Singh","year":"2016","unstructured":"Singh, J. A. & Yu, S. Allopurinol and the risk of stroke in older adults receiving medicare. BMC Neurol. 16, 164 (2016).","journal-title":"BMC Neurol."},{"key":"51724_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","volume":"400","author":"IS Mackenzie","year":"2022","unstructured":"Mackenzie, I. S. et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): A multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400, 1195\u20131205 (2022).","journal-title":"Lancet"},{"key":"51724_CR11","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S0140-6736(22)01778-0","volume":"400","author":"A Tanaka","year":"2022","unstructured":"Tanaka, A. & Node, K. Xanthine oxidase inhibition for cardiovascular disease prevention. Lancet 400, 1172\u20131173 (2022).","journal-title":"Lancet"},{"key":"51724_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41440-022-00891-7","volume":"45","author":"H Sekizuka","year":"2022","unstructured":"Sekizuka, H. Uric acid, xanthine oxidase, and vascular damage: Potential of xanthine oxidoreductase inhibitors to prevent cardiovascular diseases. Hypertens. Res. 45, 772\u2013774 (2022).","journal-title":"Hypertens. Res."},{"key":"51724_CR13","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","volume":"396","author":"IS Mackenzie","year":"2020","unstructured":"Mackenzie, I. S. et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): A multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 396, 1745\u20131757 (2020).","journal-title":"Lancet"},{"key":"51724_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2337\/dc22-1339","volume":"46","author":"B Li","year":"2023","unstructured":"Li, B. et al. Association of serum uric acid with all-cause and cardiovascular mortality in diabetes. Diabetes Care 46, 425\u2013433 (2023).","journal-title":"Diabetes Care"},{"key":"51724_CR15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White, W. B. et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N. Engl. J. Med. 378, 1200\u20131210 (2018).","journal-title":"N. Engl. J. Med."},{"key":"51724_CR16","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","volume":"40","author":"S Kojima","year":"2019","unstructured":"Kojima, S. et al. Febuxostat for cerebral and cardiorenovascular events prevention study. Eur. Heart J. 40, 1778\u20131786 (2019).","journal-title":"Eur. Heart J."},{"key":"51724_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003095","volume":"17","author":"A Tanaka","year":"2020","unstructured":"Tanaka, A. et al. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. PLOS Med. 17, e1003095 (2020).","journal-title":"PLOS Med."},{"key":"51724_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2174\/157340310791658785","volume":"6","author":"E Palomeras Soler","year":"2010","unstructured":"Palomeras Soler, E. & Casado Ruiz, V. Epidemiology and risk factors of cerebral ischemia and ischemic heart diseases: Similarities and differences. Curr. Cardiol. Rev. 6, 138\u2013149 (2010).","journal-title":"Curr. Cardiol. Rev."},{"key":"51724_CR19","volume":"14","author":"SS Lokkanahalli","year":"2022","unstructured":"Lokkanahalli, S. S., Handargal, N. H., Papali, M. M., Subash, N. & Kumar, S. Sr. Serum uric acid and lipid levels in patients with acute ischemic stroke: A cross-sectional study. Cureus 14, e28114 (2022).","journal-title":"Cureus"},{"key":"51724_CR20","doi-asserted-by":"crossref","unstructured":"Burgess, S., Davies, N. M., Thompson, S. G. & EPIC-InterAct Consortium. Instrumental variable analysis with a nonlinear exposure\u2013outcome relationship. Epidemiology 25, 877\u2013885 (2014).","DOI":"10.1097\/EDE.0000000000000161"},{"key":"51724_CR21","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1681\/ASN.2014070660","volume":"26","author":"ME Kleber","year":"2015","unstructured":"Kleber, M. E. et al. Uric acid and cardiovascular events: a Mendelian randomization study. J. Am. Soc. Nephrol. 26, 2831\u20132838 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"51724_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jacc.2015.10.086","volume":"67","author":"T Keenan","year":"2016","unstructured":"Keenan, T. et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J. Am. Coll. Cardiol. 67, 407\u2013416 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"51724_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2376","volume":"357","author":"X Li","year":"2017","unstructured":"Li, X. et al. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ 357, j2376 (2017).","journal-title":"BMJ"},{"key":"51724_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijcard.2013.11.011","volume":"170","author":"TF Chao","year":"2014","unstructured":"Chao, T. F. et al. Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation\u2014could it refine clinical risk stratification in AF?. Int. J. Cardiol. 170, 344\u2013349 (2014).","journal-title":"Int. J. Cardiol."},{"key":"51724_CR25","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1016\/j.numecd.2021.08.043","volume":"31","author":"Z Cheng","year":"2021","unstructured":"Cheng, Z. et al. High-level uric acid in asymptomatic hyperuricemia could be an isolated risk factor of cardio-cerebrovascular diseases: A prospective cohort study. Nutr. Metab. Cardiovasc. Dis. 31, 3415\u20133425 (2021).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"51724_CR26","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.2174\/1381612811319130011","volume":"19","author":"D Grassi","year":"2013","unstructured":"Grassi, D. et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr. Pharm. Des. 19, 2432\u20132438 (2013).","journal-title":"Curr. Pharm. Des."},{"key":"51724_CR27","volume":"13","author":"J Padda","year":"2021","unstructured":"Padda, J. et al. Hyperuricemia and its association with ischemic stroke. Cureus 13, e18172 (2021).","journal-title":"Cureus"},{"key":"51724_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.582680","volume":"11","author":"W Yu","year":"2020","unstructured":"Yu, W. & Cheng, J. D. Uric acid and cardiovascular disease: An update from molecular mechanism to clinical perspective. Front. Pharmacol. 11, 582680 (2020).","journal-title":"Front. Pharmacol."},{"key":"51724_CR29","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.12659\/MSM.895448","volume":"21","author":"P Su","year":"2015","unstructured":"Su, P., Hong, L., Zhao, Y., Sun, H. & Li, L. Relationship between hyperuricemia and cardiovascular disease risk factors in a Chinese population: a cross-sectional study. Med. Sci. Monit. 21, 2707\u20132717 (2015).","journal-title":"Med. Sci. Monit."},{"key":"51724_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.atherosclerosis.2008.05.047","volume":"203","author":"J Vekic","year":"2009","unstructured":"Vekic, J. et al. High serum uric acid and low-grade inflammation are associated with smaller LDL and HDL particles. Atherosclerosis 203, 236\u2013242 (2009).","journal-title":"Atherosclerosis"},{"key":"51724_CR31","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.2337\/db10-0916","volume":"60","author":"W Baldwin","year":"2011","unstructured":"Baldwin, W. et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60, 1258\u20131269 (2011).","journal-title":"Diabetes"},{"key":"51724_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12872-019-1026-2","volume":"19","author":"N Ali","year":"2019","unstructured":"Ali, N. et al. The relationship between serum uric acid and lipid profile in Bangladeshi adults. BMC Cardiovasc. Disord. 19, 42 (2019).","journal-title":"BMC Cardiovasc. Disord."},{"key":"51724_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/127596","volume":"2015","author":"TC Peng","year":"2015","unstructured":"Peng, T. C. et al. Relationship between hyperuricemia and lipid profiles in US adults. BioMed Res. Int. 2015, 127596 (2015).","journal-title":"BioMed Res. Int."},{"key":"51724_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.674398","volume":"12","author":"T Qiao","year":"2021","unstructured":"Qiao, T., Wu, H. & Peng, W. The relationship between elevated serum uric acid and risk of stroke in adult: An updated and dose-response meta-analysis. Front. Neurol. 12, 674398 (2021).","journal-title":"Front. Neurol."},{"key":"51724_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ijcard.2016.09.035","volume":"224","author":"X Lai","year":"2016","unstructured":"Lai, X. et al. Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng-Tongji cohort. Int. J. Cardiol. 224, 299\u2013304 (2016).","journal-title":"Int. J. Cardiol."},{"key":"51724_CR36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/STROKEAHA.118.023167","volume":"50","author":"DG Hackam","year":"2019","unstructured":"Hackam, D. G. & Hegele, R. A. Cholesterol lowering and prevention of stroke: An overview. Stroke 50, 537\u2013541 (2019).","journal-title":"Stroke"},{"key":"51724_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"GD Smith","year":"2003","unstructured":"Smith, G. D. & Ebrahim, S. \u2018Mendelian randomization\u2019: Can genetic epidemiology contribute to understanding environmental determinants of disease?. Int. J. Epidemiol. 32, 1\u201322 (2003).","journal-title":"Int. J. Epidemiol."},{"key":"51724_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1010823","volume":"19","author":"H Tian","year":"2023","unstructured":"Tian, H., Mason, A. M., Liu, C. & Burgess, S. Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. PLOS Genet. 19, e1010823 (2023).","journal-title":"PLOS Genet."},{"key":"51724_CR39","unstructured":"Biobank, U.J.U.B. UK Biobank Ethics and Governance Framework. 3, (2007)."},{"key":"51724_CR40","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gkz836","volume":"48","author":"S Fairley","year":"2020","unstructured":"Fairley, S., Lowy-Gallego, E., Perry, E. & Flicek, P. The international genome sample resource (IGSR) collection of open human genomic variation resources. Nucleic Acids Res. 48, D941\u2013D947 (2020).","journal-title":"Nucleic Acids Res."},{"key":"51724_CR41","doi-asserted-by":"publisher","DOI":"10.2196\/14325","volume":"7","author":"P Wu","year":"2019","unstructured":"Wu, P. et al. Mapping ICD-10 and ICD-10-CM codes to phecodes: Workflow development and initial evaluation. JMIR Med. Inform. 7, e14325 (2019).","journal-title":"JMIR Med. Inform."},{"key":"51724_CR42","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/sim.6835","volume":"35","author":"S Burgess","year":"2016","unstructured":"Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on multiple instrumental variables in Mendelian randomization: Comparison of allele score and summarized data methods. Stat. Med. 35, 1880\u20131906 (2016).","journal-title":"Stat. Med."},{"key":"51724_CR43","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.ajhg.2021.05.014","volume":"108","author":"H Xue","year":"2021","unstructured":"Xue, H., Shen, X. & Pan, W. Constrained maximum likelihood-based Mendelian randomization robust to both correlated and uncorrelated pleiotropic effects. Am. J. Hum. Genet. 108, 1251\u20131269 (2021).","journal-title":"Am. J. Hum. Genet."},{"key":"51724_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang, C. C. et al. Second-generation PLINK: Rising to the challenge of larger and richer datasets. GigaScience 4, 7 (2015).","journal-title":"GigaScience"},{"key":"51724_CR45","doi-asserted-by":"publisher","first-page":"e34408","DOI":"10.7554\/eLife.34408","volume":"7","author":"G Hemani","year":"2018","unstructured":"Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife 7, e34408 (2018).","journal-title":"eLife"},{"key":"51724_CR46","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/ije\/dyx034","volume":"46","author":"OO Yavorska","year":"2017","unstructured":"Yavorska, O. O. & Burgess, S. MendelianRandomization: An R package for performing Mendelian randomization analyses using summarized data. Int. J. Epidemiol. 46, 1734\u20131739 (2017).","journal-title":"Int. J. Epidemiol."},{"key":"51724_CR47","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1093\/ije\/dyac150","volume":"51","author":"AM Mason","year":"2022","unstructured":"Mason, A. M. & Burgess, S. Software application profile: SUMnlmr, an R package that facilitates flexible and reproducible non-linear Mendelian randomization analyses. Int. J. Epidemiol. 51, 2014\u20132019 (2022).","journal-title":"Int. J. Epidemiol."},{"key":"51724_CR48","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1001\/jama.2021.18236","volume":"326","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova, V. W. et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement. JAMA 326, 1614\u20131621 (2021).","journal-title":"JAMA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51724-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51724-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51724-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T21:34:06Z","timestamp":1705700046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51724-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51724"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51724-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"10 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.K., S.Y.L., J.L., S.Y., E.G.K., E.L., S.L., and H.G. are employees of Basgenbio Inc., Seoul, Republic of Korea. S-I.P. has served on advisory boards for Basgenbio Inc., Seoul, Republic of Korea. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1338"}}